Article Text

PDF
S28 Liraglutide 3.0 Mg Reduces Severity Of Obstructive Sleep Apnoea And Body Weight In Obese Individuals With Moderate Or Severe Disease: Scale Sleep Apnoea Trial
  1. A Collier1,
  2. A Blackman2,
  3. G Foster3,
  4. G Zammit4,
  5. R Rosenberg5,
  6. T Wadden6,
  7. L Aronne7,
  8. B Claudius8,
  9. T Jensen8,
  10. E Mignot9
  1. 1Ayr Hospital, Ayr, UK
  2. 2Toronto Sleep Institute, MedSleep, Toronto, Canada
  3. 3Temple University, Philadelphia, USA
  4. 4Clinilabs Sleep Disorders Institute, New York, USA
  5. 5NeuroTrials Research, Atlanta, USA
  6. 6University of Pennsylvania, Philadelphia, USA
  7. 7Weill Cornell Medical College, New York, USA
  8. 8Novo Nordisk A/S, Søborg, Denmark
  9. 9Stanford University, Palo Alto, USA

Abstract

Aims/objectives This randomised, double-blind, parallel-group trial compared the effects of liraglutide 3.0 mg to placebo, both as adjunct to diet and exercise, on obstructive sleep apnoea (OSA) severity and body weight.

Content Obese individuals (n = 359) without diabetes who had moderate or severe OSA and were unwilling/unable to use continuous positive airway pressure therapy were randomised 1:1 to liraglutide 3.0 mg or placebo for 32 weeks (baseline characteristics: 48.5 years, males 71.9%, apnoea–hypopnoea index [AHI] 49.2 events/h, body weight 117.6 kg, BMI 39.1 kg/m2, HbA1c 5.7%).

Outcomes At end-of-trial, the reduction in AHI was significantly greater with liraglutide 3.0 mg than placebo (Table). Liraglutide 3.0 mg produced significantly greater weight loss compared with placebo (Table) and enabled more individuals to reach ≥5% and >10% weight loss targets after 32 weeks (p < 0.0001, both). Oxygen saturation, polysomnographic measures, HbA1c and systolic blood pressure (SBP) at 32 weeks are summarised (Table). Nausea and diarrhoea were the most common adverse events with liraglutide 3.0 mg (27% and 17% of individuals, respectively).

Discussion Liraglutide 3.0 mg produced significantly greater reductions than placebo in AHI, body weight, SBP and HbA1c in obese individuals with moderate/severe OSA and was generally well tolerated.

Abstract S28 Table 1

Change from baseline at 32 weeks

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.